Spark, Pfizer amend agreement for experimental hemophilia gene therapy

Spark Therapeutics and Pfizer Inc. have amended their license agreement for an experimental gene therapy for hemophilia B — which could result in additional payments of up to $25 million for Spark. Under the amended agreement, Spark Therapeutics, a Philadelphia gene therapy company spun out of Children’s Hospital of Philadelphia, will enroll up to five additional participants in the current phase-I/II clinical tri al testing the treatment known as SPK-9001. The new participants will receive…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news